The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is rec...
Saved in:
Main Author: | K. E. Borisov (Author) |
---|---|
Format: | Book |
Published: |
ABV-press,
2014-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recurrent ovarian cancer: prolongation of the platinum-free interval with the use of a weekly treatment regimen of hycamtin (topotecan)
by: E. G. Novikova, et al.
Published: (2014) -
Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life
by: E. G. Novikova, et al.
Published: (2014) -
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
by: Zhongmian Pan, et al.
Published: (2023) -
The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: The Kaohsiung Chang Gung experience
by: Ching-Fen Hu, et al.
Published: (2015) -
The role of topotecan in cancer ginecology treatment
by: A. G. Kedrova, et al.
Published: (2017)